IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1226-1250 out of 1316.

<< < 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

Public Release: 12-Mar-2015
European Radiology
Low breast density in mammography worsens breast cancer prognosis
Very low mammographic breast density worsens the prognosis of breast cancer, according to a recent study from the University of Eastern Finland. Disease free survivals as well as overall life expectancies were significantly shorter in women with very low-density breasts in comparison to women with high-density breast tissue. The lower the breast tissue density, the less fibroglandular tissue there is compared to fat tissue.

Contact: Ritva Vanninen
ritva.vanninen@kuh.fi
358-447-113-303
University of Eastern Finland

Public Release: 12-Mar-2015
JAMA Oncology
Geography matters: Imaging overuse seen in certain US regions
Researchers from NYU Langone Medical Center conclude that patients with low-risk prostate or breast cancer were more likely to receive inappropriate imaging during treatment, based on the region of the country in which they received medical care.
Robert Wood Johnson Foundation, Louis Feil Charitable Lead Trust, US Department of Veterans Affairs

Contact: Jim Mandler
jim.mandler@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine

Public Release: 12-Mar-2015
Cancer
Reaching '80 percent by 2018' would prevent more than 20,000 colorectal cancer deaths per year
Increasing colorectal cancer screening rates to 80 percent by 2018 would prevent an additional 21,000 colorectal cancer deaths per year by 2030, according to a new study.
NIH/National Cancer Institute, American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 12-Mar-2015
JAMA Oncology
Germline TP53 mutations in patients with early-onset colorectal cancer
In a group of patients diagnosed with colorectal cancer at 40 or younger, 1.3 percent of the patients carried germline TP53 gene mutations, although none of the patients met the clinical criteria for an inherited cancer syndrome associated with higher lifetime risks of multiple cancers, according to a study published online by JAMA Oncology.

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
The JAMA Network Journals

Public Release: 12-Mar-2015
JAMA Oncology
Study examines association of inappropriate prostate, breast cancer imaging
An association of high rates of inappropriate imaging for prostate cancer and breast cancer identified in a study of Medicare beneficiaries suggests that, at the regional level, regional culture and infrastructure could contribute to inappropriate imaging, something policymakers should want to consider as they seek to improve the quality of care and reduce health care spending, according to a study published online by JAMA Oncology.

Contact: Jim Mandler
jim.mandler@nyumc.org
212-404-3525
The JAMA Network Journals

Public Release: 12-Mar-2015
Science
Magnetic brain stimulation
Magnetic nanoparticles could allow brain stimulation without wires.

Contact: Andrew Carleen
acarleen@mit.edu
617-253-1682
Massachusetts Institute of Technology

Public Release: 12-Mar-2015
Cell Reports
New genome-editing technology to help treat blood cancers
Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy. Using the technology, researchers from the Walter and Eliza Hall Institute were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
National Health and Medical Research Council, Leukaemia Foundation, Kay Kendall Leukemia Fund and Victorian Government.

Contact: Liz Williams
williams@wehi.edu.au
61-428-034-089
Walter and Eliza Hall Institute

Public Release: 12-Mar-2015
Cell Reports
Stem cells lurking in tumors can resist treatment
Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment. For the first-time, scientists at Washington University School of Medicine in St. Louis have isolated treatment-resistant cancer stem cells from low-grade tumors.

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine

Public Release: 11-Mar-2015
PLOS ONE
Molecules in prostate tumors might predict whether RT can help prevent recurrence
A new study has identified a group of molecules in prostate-cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 11-Mar-2015
Nature
Tetanus shot improves patient survival with brain tumor immunotherapy
An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.
NIH/National Institute of Neurological Disorders and Stroke, National Institutes of Health

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 11-Mar-2015
Nature
'Quantum jitters' could form basis of evolution, cancer
Duke researchers have discovered 'quantum jitters,' in which DNA's four basic building blocks temporarily change shapes, fooling DNA-replication machinery into making a copying mistake. This shape-shifting is exceedingly rare and only flickers into existence for a thousandth of a second. But these jitters occur with the same frequency as DNA copying mistakes, a hint that this might be the basis of the genetic mutations that drive evolution and diseases like cancer.
National Institutes of Health, Agilent Thought Leader Award

Contact: Karl Bates
karl.bates@duke.edu
919-681-8054
Duke University

Public Release: 11-Mar-2015
Cancer Prevention Research
Naproxen plus acid-blocking drug shows promise in preventing bladder cancer
Researchers used the proton pump inhibitor omeprazole, a commonly used acid inhibitor, in combination with naproxen and found it was effective at preventing bladder cancer in an animal model.
NIH/National Cancer Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 11-Mar-2015
Nature Communications
Honey, I shrunk the ants: How environment controls size
Until now scientists have believed that the variations in traits such as our height, skin colour, tendency to gain weight or not, intelligence, tendency to develop certain diseases, etc., all of them traits that exist along a continuum, were a result of both genetic and environmental factors. But they didn't know how exactly these things worked together. By studying ants, McGill researchers have identified a key mechanism by which epigenetic factors influence the expression of all of these traits.

Contact: Katherine Gombay
katherine.gombay@mcgill.ca
McGill University

Public Release: 11-Mar-2015
Epidemics
Urging HPV vaccine for boys could protect more people at same price
Whether vaccinating US boys against HPV in addition to girls is worth the cost has been hotly debated. But with HPV-related cancers in men on the rise, and coverage in girls stagnating below the levels needed to ensure that most people are protected, research suggests that devoting a portion of HPV funding to boys -- rather than merely attempting to improve female coverage -- may protect more people for the same price.
National Institutes of Health, National Science Foundation, Duke University

Contact: Robin Ann Smith
ras10@duke.edu
919-681-8057
Duke University

Public Release: 11-Mar-2015
Journal of Thoracic Oncology
Concurrent chemoradiation treatment at high-volume facilities improves survival for NSCLC
Patients treated with definitive concurrent chemotherapy and radiation therapy for stage III non-small cell lung cancer have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.

Contact: Murry Wynes
Murry.Wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 11-Mar-2015
PLOS Pathogens
Deadly to cancer cells only
Parvoviruses can destroy cancer cells and are currently being tested in a preliminary clinical trial to treat malignant brain cancer. For their replication, the viruses need a particular enzyme in the cell. Scientists from the German Cancer Research Center have now discovered that in healthy human cells, parvoviruses are unable to activate this enzyme. In many cases of malignant brain cancer, however, the enzyme is permanently active. As a result, this enables the viruses to replicate and to destroy the cancer cells.

Contact: Dr. Sibylle Kohlstädt
s.kohlstaedt@dkfz.de
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Public Release: 10-Mar-2015
eLife
Scientists show proteins critical in day-night cycles also protect cells from mutations
New research from The Scripps Research Institute shows that two proteins critical for maintaining healthy day-night cycles also protect against mutations that could lead to cancer. The new study shows that the two proteins have an unexpected role in DNA repair, possibly protecting cells from cancer-causing mutations triggered by UV radiation.
Searle Scholars Fund, Sidney Kimmel Foundation for Cancer Research, Lung Cancer Research Foundation, NIH/National Institute of General Medical Sciences, NIH/National Institute on Aging, NIH/National Institute of Diabetes, Digestive and Kidney Diseases

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 10-Mar-2015
New Journal of Physics
Fractal patterns may uncover new line of attack on cancer
Studying the intricate fractal patterns on the surface of cells could give researchers a new insight into the physical nature of cancer, and provide new ways of preventing the disease from developing.

Contact: Michael Bishop
michael.bishop@iop.org
01-179-301-032
Institute of Physics

Public Release: 10-Mar-2015
Cancer Immunology Research
Engineered cells could help tackle the third most common cancer in Chinese males
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of nasopharyngeal carcinoma patients.
Cancer Research UK Senior Cancer Fellowship Award, Hong Kong Cancer Fund

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 10-Mar-2015
American Journal of Gastroenterology
Regenstrief study finds natural language processing accurately tracks colonoscopy quality
An accurate system for tracking the quality of colonoscopies and determining the appropriate intervals between these procedures could contribute to both better health outcomes and lower costs. Clinician-researchers from the Regenstrief Institute have created and tested such a system in the nation's first multiple institution colonoscopy quality measurement study utilizing natural language processing and report that it is as accurate but less expensive than human review.
VA Merit Review Grant, American Society for Gastrointestinal Endoscopy Covidien Senior Investigator Mentoring and Career Development Awards, Mamlin-McDonald Biomedical Informatics Fellowship, Regenstrief Institute Innovations Award

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-843-2276
Indiana University

Public Release: 10-Mar-2015
International Journal of Radiation Oncology • Biology • Physics
Clinical trial suggests combination therapy is best for low-grade brain tumors
New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 10-Mar-2015
Cancer Cell
Study explains control of cell metabolism in patient response to breast cancer drugs
Researchers identify a control mechanism for glutamine uptake in breast cancer cells and its importance for response to select chemotherapies.
National Institutes of Health

Contact: Susan Gammon
sgammon@sanfordburnham.org
858-795-5012
Sanford-Burnham Prebys Medical Discover Institute

Public Release: 9-Mar-2015
Journal of Clinical Investigation
From brain tumors to memory: A very multifunctional protein
A protein called BAI1 involved in limiting the growth of brain tumors is also critical for spatial learning and memory, researchers have discovered. BAI1 is part of a regulatory network neuroscientists think is connected with autism spectrum disorders.
NIH/National Cancer Institute, NIH/National Institute of Neurological Disorders and Stroke, Southeastern Brain Tumor Foundation, St. Baldricks

Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences

Public Release: 9-Mar-2015
Nature Communications
Researchers map 'genomic landscape' of childhood adrenocortical tumors for the first time
In an advance that could lead to better identification of malignant pediatric adrenocortical tumors, and ultimately to better treatment, researchers have mapped the 'genomic landscape' of these rare childhood tumors. Their genomic mapping has revealed unprecedented details, not only of the aberrant genetic and chromosomal changes that drive the cancer, but the sequence of those changes that trigger it.
Washington University Pediatric Cancer Genome Project, Kay Jewelers, National Institutes of Health, NIH/National Cancer Institute, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
90-159-502-295
St. Jude Children's Research Hospital

Public Release: 9-Mar-2015
DNA and Cell Biology
Viagra in combination with new drugs can have anti-cancer, antibacterial, and therapeutic effects
Chaperone proteins play an important role in protein folding in human cells and in bacteria and are promising new targets for drugs to treat cancer and Alzheimer's disease and for novel antiviral drugs and antibiotics. How existing drugs such as Viagra or Cialis and a derivative of the drug Celebrex, for example, can reduce the activity of a specific chaperone protein, with the potential for anti-tumor and anti-Alzheimer's disease effects, is described in a Review article in DNA and Cell Biology.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Showing releases 1226-1250 out of 1316.

<< < 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 > >>

  Search News Releases

     

 

EurekAlert!